152 related articles for article (PubMed ID: 29498983)
1. Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study.
Selle F; Colombo N; Korach J; Mendiola C; Cardona A; Ghazi Y; Oza AM
Int J Gynecol Cancer; 2018 May; 28(4):729-737. PubMed ID: 29498983
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
Oza AM; Selle F; Davidenko I; Korach J; Mendiola C; Pautier P; Chmielowska E; Bamias A; DeCensi A; Zvirbule Z; González-Martín A; Hegg R; Joly F; Zamagni C; Gadducci A; Martin N; Robb S; Colombo N
Int J Gynecol Cancer; 2017 Jan; 27(1):50-58. PubMed ID: 27749456
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Gonzalez-Martin A; Gladieff L; Tholander B; Stroyakovsky D; Gore M; Scambia G; Kovalenko N; Oaknin A; Ronco JP; Freudensprung U; Pignata S;
Eur J Cancer; 2013 Dec; 49(18):3831-8. PubMed ID: 24007819
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
Garcia Garcia Y; de Juan Ferré A; Mendiola C; Barretina-Ginesta MP; Gaba Garcia L; Santaballa Bertrán A; Bover Barcelo I; Gil-Martin M; Manzano A; Rubio Pérez MJ; Romeo Marin M; Arqueros Núñez C; García-Martínez E; Gonzalez Martin A
Int J Gynecol Cancer; 2019 Jul; 29(6):1050-1056. PubMed ID: 31263024
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
Sorio R; Roemer-Becuwe C; Hilpert F; Gibbs E; García Y; Kaern J; Huizing M; Witteveen P; Zagouri F; Coeffic D; Lück HJ; González-Martín A; Kristensen G; Levaché CB; Lee CK; Gebski V; Pujade-Lauraine E;
Gynecol Oncol; 2017 Jan; 144(1):65-71. PubMed ID: 27871723
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390).
Laskin J; Crinò L; Felip E; Franke F; Gorbunova V; Groen H; Jiang GL; Reck M; Schneider CP
J Thorac Oncol; 2012 Jan; 7(1):203-11. PubMed ID: 22173662
[TBL] [Abstract][Full Text] [Related]
7. Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study.
Korach J; Colombo N; Mendiola C; Selle F; Dolado I; Donica M; Oza AM
J Surg Oncol; 2019 Sep; 120(4):786-793. PubMed ID: 31368160
[TBL] [Abstract][Full Text] [Related]
8. Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study.
Hall M; Bertelli G; Li L; Green C; Chan S; Yeoh CC; Hasan J; Jones R; Ograbek A; Perren TJ
Int J Gynecol Cancer; 2020 Feb; 30(2):213-220. PubMed ID: 31780570
[TBL] [Abstract][Full Text] [Related]
9. A Real-Life Experience of Bevacizumab in Elderly Women With Advanced Ovarian Carcinoma.
Beinse G; Emile G; Cessot A; Boudou-Rouquette P; Huillard O; Saidu NE; Borghese B; Goldwasser F; Pujade Lauraine E; Alexandre J
Int J Gynecol Cancer; 2016 Sep; 26(7):1196-200. PubMed ID: 27643645
[TBL] [Abstract][Full Text] [Related]
10. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
Hoskins P; Vergote I; Cervantes A; Tu D; Stuart G; Zola P; Poveda A; Provencher D; Katsaros D; Ojeda B; Ghatage P; Grimshaw R; Casado A; Elit L; Mendiola C; Sugimoto A; D'Hondt V; Oza A; Germa JR; Roy M; Brotto L; Chen D; Eisenhauer EA
J Natl Cancer Inst; 2010 Oct; 102(20):1547-56. PubMed ID: 20937992
[TBL] [Abstract][Full Text] [Related]
11. Frontline use of bevacizumab in ovarian cancer: Experience from India.
Vatsa R; Kumar L; Kumar S; Roy KK; Singh N; Meena J
Natl Med J India; 2018; 31(1):15-18. PubMed ID: 30348916
[TBL] [Abstract][Full Text] [Related]
12. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial.
Sabatier R; Rousseau F; Joly F; Cropet C; Montégut C; Frindte J; Cinieri S; Guerra Alía EM; Polterauer S; Yoshida H; Vergote I; Colombo N; Hietanen S; Largillier R; Canzler U; Gratet A; Marmé F; Favier L; Pujade-Lauraine E; Ray-Coquard I
Eur J Cancer; 2023 Mar; 181():42-52. PubMed ID: 36634389
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and Efficacy of Bevacizumab Monotherapy in Older Patients With Recurrent Ovarian Cancer.
Shintani D; Yoshida H; Yabuno A; Fujiwara K
In Vivo; 2020; 34(3):1451-1457. PubMed ID: 32354945
[TBL] [Abstract][Full Text] [Related]
16. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
17. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
Zinner RG; Obasaju CK; Spigel DR; Weaver RW; Beck JT; Waterhouse DM; Modiano MR; Hrinczenko B; Nikolinakos PG; Liu J; Koustenis AG; Winfree KB; Melemed SA; Guba SC; Ortuzar WI; Desaiah D; Treat JA; Govindan R; Ross HJ
J Thorac Oncol; 2015 Jan; 10(1):134-42. PubMed ID: 25371077
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab for Ovarian Cancer at High Risk of Progression: Reproducibility of Trial Results in 'Real-world' Patients.
Bertelli G; Drews F; Lutchman-Singh K
Anticancer Res; 2016 Sep; 36(9):4947-50. PubMed ID: 27630353
[TBL] [Abstract][Full Text] [Related]
19. The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab.
Boisen MK; Madsen CV; Dehlendorff C; Jakobsen A; Johansen JS; Steffensen KD
Int J Gynecol Cancer; 2016 Oct; 26(8):1390-8. PubMed ID: 27648712
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Wu YS; Shui L; Shen D; Chen X
Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
